A personalized melanoma vaccine strengthens immunotherapy

A personalized melanoma vaccine has shown that tailoring treatment to the mutations in an individual patient's tumor can meaningfully improve outcomes after cancer surgery.

In a large Phase 3 clinical trial, adding an experimental mRNA vaccine to standard immunotherapy reduced the relative risk of melanoma recurrence or death by 42%.

The treatment is unusual because every vaccine is different. Rather than targeting a shared cancer marker, it is manufactured using genetic information from the patient's own tumor.

The findings come from INTerpath-001, an international clinical trial conducted by Moderna and Merck involving 1,137 patients with high-risk cutaneous melanoma whose tumors had been completely removed.

The detailed results were released on October 22, 2026, ahead of their scheduled presentation at the European Society for Medical Oncology (ESMO) Congress.

At two years, 82.2% of patients receiving the personalized vaccine alongside immunotherapy remained free from recurrence, compared with 70.0% of those receiving immunotherapy alone.

That represents an absolute difference of 12.2 percentage points.

The distinction matters. The widely reported 42% figure describes the relative reduction in the hazard of recurrence or death during follow-up, not a 42-percentage-point improvement in the proportion of patients remaining cancer-free.

A vaccine designed after the tumor is removed

Conventional vaccines are manufactured in standardized batches. Millions of people can receive essentially the same product.

A personalized cancer vaccine works differently. Its composition cannot be finalized until a patient's tumor has been examined.

The experimental treatment, known as intismeran autogene, V940, or mRNA-4157, begins with a tumor sample. Scientists sequence its genetic material and compare it with the patient's normal DNA.

Cancer cells acquire mutations as they evolve. Some mutations alter the proteins those cells produce, creating fragments called neoantigens.

Because these fragments differ from normal human proteins, they can provide recognizable targets for the immune system.

The challenge is selecting which mutations are most likely to provoke a useful immune response.

For intismeran, scientists identify candidate neoantigens and manufacture a customized messenger RNA molecule encoding up to 34 of them.

After vaccination, cells temporarily produce the selected antigenic material. Immune cells can then process and present these fragments, potentially activating T cells capable of recognizing cancer cells carrying the corresponding mutations.

The aim is to help the immune system identify and eliminate malignant cells that may remain after surgery.

This is a therapeutic vaccine, not a conventional preventive vaccine given to healthy individuals. It is being investigated in people who have already developed cancer and undergone treatment.

Why the vaccine was paired with Keytruda

Recognition alone is not always sufficient for an effective anti-cancer immune response.

Tumors can suppress T-cell activity through immune checkpoint pathways, including the PD-1 signaling system. Under normal circumstances, these checkpoints prevent excessive or harmful immune activation.

Pembrolizumab, marketed as Keytruda, blocks PD-1 and helps restore anti-tumor T-cell activity.

Combining it with a personalized vaccine creates a complementary strategy.

The vaccine is intended to stimulate T cells against patient-specific tumor antigens. Pembrolizumab helps prevent inhibitory signals from limiting their activity.

The Phase 3 trial was designed to determine whether this combination provides a meaningful benefit beyond pembrolizumab alone.

Patients were randomly assigned in a 2:1 ratio. The experimental group included 757 people who received intismeran plus pembrolizumab. The control group included 380 people who received pembrolizumab and a placebo injection.

The study was double-blind, reducing the likelihood that knowledge of treatment assignment would influence care or outcome assessment.

Patients could receive up to nine vaccine doses at three-week intervals. Pembrolizumab was administered every six weeks for approximately one year.

Importantly, both groups received an established immunotherapy. The comparison therefore measured the additional benefit associated with the personalized vaccine.

The numbers behind the Phase 3 result

After a median follow-up of 24.6 months, the combination demonstrated a statistically significant improvement in recurrence-free survival.

The hazard ratio for recurrence or death was 0.58, corresponding to a 42% relative reduction compared with pembrolizumab alone.

A second important endpoint examined distant metastasis-free survival: how long patients remained alive without cancer spreading to distant parts of the body.

Here, too, the combination performed better.

The relative risk of distant metastasis or death was reduced by 38%. At two years, 88.5% of patients in the combination group remained free of distant metastases, compared with 80.2% in the control group.

The timing of the benefit adds an interesting dimension.

During the first six months, the risk of recurrence or death was similar between treatment groups. A prespecified additional analysis focusing on events after six months found a larger separation in outcomes.

This pattern is compatible with the possibility that a personalized vaccine requires time and repeated administration to generate a sufficiently broad immune response.

However, the timing analysis does not establish that mechanism. The later difference could also be influenced by factors related to the analysis itself.

Additional treatment also brings additional adverse effects.

Fever was reported in 52.2% of patients receiving the vaccine combination, compared with 8.2% in the control group. Injection-site pain was also considerably more frequent.

Severe treatment-related adverse events occurred in 14.2% and 13.4% of patients, respectively.

These figures are important when considering the overall balance between treatment benefit, additional injections, and tolerability.

One major clinical question remains unresolved: overall survival.

Although investigators reported a favorable trend, the available data are not yet mature enough to establish whether adding the vaccine helps patients live longer overall.

Intismeran also remains an investigational therapy rather than an approved standard treatment. The complete Phase 3 findings have been accepted for publication in The New England Journal of Medicine, while continued follow-up will provide longer-term outcomes.

Even with these limitations, the trial represents an important milestone. It provides randomized Phase 3 evidence that an individualized mRNA neoantigen therapy can improve recurrence-related outcomes when added to an established cancer treatment.

Its significance is particularly clear in the postoperative setting.

Removing a visible tumor does not always eliminate every malignant cell. Small numbers of surviving cancer cells can remain undetected and later give rise to recurrence.

Personalized vaccination attempts to turn the genetic information obtained from the removed tumor into a lasting immunological advantage.

The tumor may be gone, but its mutations can still help guide the immune system toward the cells that could bring it back.